A multinational pharmaceutical company was planning to introduce its first commercial product into the EU’s Big 5 markets.
Although it had only one product, it was planning to set up a traditional organization of FTEs that would cost around $25 million over the first three years.
We developed a series of fully-costed alternatives to FTEs that would provide the necessary sales, marketing, regulatory, finance and pharmacovigilance functions.
The option we recommended was a virtual commercial organization, in which all but core functions were identified and sourced from service providers which we identified, screened and approved.
Our feasibility study and implementation plan saved more than 40% over the company’s initial concept for a traditional structure.